Navigation Links
Global Med Technologies(R) Announces Second Quarter and First Half Results
Date:8/13/2009

DENVER, Aug. 13 /PRNewswire-FirstCall/ -- Global Med Technologies(R), Inc. ("Global Med" or the "Company") (OTC Bulletin Board: GLOB), an international healthcare information technology company, today reported its operating results for the three and six months ended June 30, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO)

Global Med's record revenues of $16.418 million for the first half of 2009 represent an increase of $6.980 million or 74% over the $9.438 million recorded for the first half of 2008. In the first half of 2009, operating income improved to $1.678 million from $958 thousand during the first half of last year. The Company's net income for the first half of 2009 was $593 thousand, or $0.02 per basic common share outstanding, versus $512 thousand, or $0.02 per basic common share outstanding, for the first half of 2008.

Global Med's revenues of $8.059 million for the second quarter of 2009 represent an increase of $3.214 million or 66% over the $4.845 million recorded for the comparable 2008 period. In the second quarter of 2009, operating income improved to $621 thousand from $333 thousand during the comparable 2008 period. The Company's net income for the second quarter of 2009 increased 79% to $272 thousand, or $0.01 per basic common share outstanding, from $152 thousand, or $0.01 per basic common share outstanding, for the comparable 2008 period.

While the Company's acquisitions of Inlog and eDonor in 2008 were the primary drivers of revenue growth in both the second quarter and half year results, the solid operating performance of the Company's Wyndgate Division was the primary driver of the improvement in operating income for both periods.

Global Med's cash flow from operations for the first half of 2009 was $3.891 million, a more than four-fold increase over the $887 thousand recorded for the first half of 2008.

Recurring annual maintenance revenues for the quarter were running at an annualized rate of over $16.7 million. Based on the backlog as of June 30, 2009, the Company's annual recurring revenues, when all contracted customer sites are implemented, will be nearly $18.0 million, an increase of 20% over 2008. The Company's backlog of unrecognized software license fees and implementation fees as of June 30, 2009 was approximately $8.8 million, an increase of 59% over 2008.

Second Quarter 2009 Business Developments and Announcements:

  • Mid-year 2009 KLAS survey scores placed Global Med's Wyndgate division first in its class for its blood donor center and hospital transfusion software.
  • During the quarter, the Company announced the licensing of its SafeTraceTx software to a 40 hospital healthcare organization in the Southeast.
  • The Company completed a three-year contract extension with a significant channel partner.
  • Another major channel partner began selling the Company's eDonor products and services, worldwide.
  • Global Med continues to roll out blood bank software solutions for CHS, signing multiple new licenses and completing additional implementations during the quarter.
  • Global Med's Inlog subsidiary licensed its EdgeLab laboratory information management software (marketed as "Labo Serveur" in France) to the Eugene Andre Hospital near Lyon, France.

Mick Ruxin, M.D., Chairman and CEO of Global Med Technologies, Inc., commenting on today's announcement stated, "The Company continues to increase revenue and profits in spite of the difficult economic climate. While the sales cycle has lengthened in the United States, we are pleased with the strong sales bookings we are achieving in Europe and elsewhere. We believe that our Inlog acquisition has positioned us to benefit from the strong demand we see overseas for our suite of innovative products. Our Wyndgate division also performed well during the quarter where our focus on productivity and efficiency yielded cost savings that flowed to the bottom line."

Thomas F. Marcinek, the Company's President and COO, stated, "Global Med continues to execute on its business plan. Although the sales climate is challenging in the U.S., we believe we are on track to meet our annual sales objectives. Our customers continue to validate our products and customer service which translates into a strong and sustainable recurring revenue stream and serves as a platform for new system sales as well."

The Company will host a conference call today at 11:00 a.m. Eastern. Mick Ruxin, M.D., CEO, Tom Marcinek, President and COO, and Karen Davis, CFO, will discuss the second quarter financial results and will be available to answer questions. Interested parties are welcome to call the following telephone numbers five minutes prior to the start of the conference call. Callers within the U.S. should call: 1-866-394-9731. Callers that are outside of the U.S. should call: 1-706-643-7541. Callers should reference "Global Med Second Quarter Financial Results" to the conference call operator. The conference call ID number will be: 21830805.

Internet access to the call will be available on the Company's web site at www.globalmedtech.com. The webcast replay will be available until Thursday, August 27, 2009.

An automated replay of the conference call will be available from Thursday, August 13, 2009 at 5:30 p.m. EDT until Monday, August 17, 2009 at 11:59 p.m. EDT. To access the replay, callers within the U.S. should call: 1-800-642-1687. Callers outside of the U.S. should call: 1-706-645-9291 and enter Global Med's access code of 21830805. The replay of the conference call will be available from August 17, 2009 onward at Global Med's website at www.globalmedtech.com.

The following tables provide information related to the Company's operations for the three and six months ended June 30, 2009 and 2008:




           GLOBAL MED TECHNOLOGIES, INC. (OTC Bulletin Board: GLOB.OB)

                    Selected Operating Results (Unaudited)
                         Three Months Ended June 30,
                    In (000s) Except Per Share Information

                                             2009             2008
                                             ----             ----
    Revenues                               $8,059           $4,845
    --------                               ------           ------
    Cost of revenues                        3,167            1,860
    ----------------                         -----            -----
    Operating expenses                      4,271            2,652
    ------------------                      -----            -----
    Income from operations                    621              333
    ----------------------                    ---              ---
    Other income (expense), net              (191)               8
    ---------------------------              ----              ---
    Income taxes                             (158)            (189)
    ------------                             ----             ----
    Net income                               $272             $152
    ----------                               ----             ----
    Income per share:
      Basic                                 $0.01            $0.01
      Diluted                               $0.01            $0.00
      -------                               -----            -----
    Weighted-average shares outstanding:
      Basic                                34,346           27,948
      Diluted                              44,267           46,875
      -------                              ------           ------



                      Selected Operating Results (Unaudited)
                            Six Months Ended June 30,
                    In (000s) Except Per Share Information

                                             2009             2008
                                             ----             ----
    Revenues                              $16,418           $9,438
    --------                              -------           ------
    Cost of revenues                        6,207            3,418
    ----------------                        -----            -----
    Operating expenses                      8,533            5,062
    ------------------                      -----            -----
    Income from operations                  1,678              958
    ----------------------                  -----              ---
    Other income (expense), net              (379)              38
    ---------------------------              ----              ---
    Income taxes                             (706)            (484)
    ------------                             ----             ----
    Net income                               $593             $512
    ----------                               ----             ----
    Income per share:
      Basic                                 $0.02            $0.02
      Diluted                               $0.01            $0.01
      -------                               -----            -----
    Weighted-average shares outstanding:
      Basic                                34,218           27,442
      Diluted                              44,138           45,882
      -------                              ------           ------



             GLOBAL MED TECHNOLOGIES, INC. (OTC Bulletin Board: GLOB.OB)

                   Selected Cash Flow Information (Unaudited)
                           Six Months Ended June 30,
                                   In (000s)

                                             2009             2008
                                             ----             ----
    Cash flows provided by (used in):
    ----------------------------
      Operations                           $3,891             $887
      ----------                           ------             ----
      Investing activities                   (304)          (6,260)
      --------------------                   ----           ------
      Financing activities                 (1,133)           6,790
      --------------------                 ------            -----
      Effect of exchange rates on cash         41                -
      --------------------------------        ---              ---
    Net increase (decrease) in cash         2,495            1,417
    -------------------------------         -----            -----
    Cash, beginning of period               4,472            6,748
    -------------------------               -----            -----
    Cash, end of period                    $6,967           $8,165
    -------------------                    ------           ------



                 Selected Balance Sheet Information (Unaudited)
                                    June 30,
                                   In (000s)

                                             2009             2008
                                             ----             ----
    Cash, cash equivalents and
     marketable securities                 $7,275           $4,660
    --------------------------             ------           ------
    Other current assets                    7,073            9,566
    --------------------                    -----            -----
    Current assets                         14,348           14,226
    --------------                         ------           ------
    PP&E                                    1,315            1,385
    ----                                    -----            -----
    Intangible assets                      13,905           14,081
    -----------------                      ------           ------
    Other long-term assets                    113               92
    ----------------------                    ---              ---
    Total assets                          $29,681          $29,784
    ------------                          -------          -------

    Accounts payable, accrued expenses
     and other current liabilities         $7,040           $6,759
    ----------------------------------     ------           ------
    Deferred revenue                        6,013            6,361
    ----------------                        -----            -----
    Current portion of long-term debt       2,323            2,335
    ---------------------------------       -----            -----
    Total current liabilities              15,376           15,455
    -------------------------              ------           ------
    Long-term debt                          6,238            7,853
    --------------                          -----            -----
    Other long-term liabilities             1,072            1,065
    ---------------------------             -----            -----
    Total liabilities                      22,686           24,373
    -----------------                      ------           ------

    Total stockholders' equity              6,995            5,411
    --------------------------              -----            -----
    Total liabilities and
     stockholders' equity                 $29,681          $29,784
    ---------------------                 -------          -------


About Global Med Technologies(R), Inc.

Global Med Technologies, Inc. is an international healthcare information technology company which develops regulated and non-regulated products and services for the healthcare industry. As a leading provider of blood and laboratory systems and services, Global Med's products are deployed in 20 countries and serve over 2,100 transfusion centers, blood banks and laboratory sites.

Global Med's domestic companies are Wyndgate Technologies(R), a leader in software products and services for donor centers and hospital transfusion services; eDonor(R), which offers web-based donor relationship management systems; and PeopleMed(R), Inc., which implements cost-effective software validation, consulting and compliance solutions to hospitals and donor centers.

Global Med's European subsidiary, Inlog, SA, is a leading developer of donor center and transfusion management systems as well as cellular therapy software, laboratory information systems and quality assurance medical software systems internationally.

For more information about Global Med's products and services, please call 800-996-3428 or visit www.globalmedtech.com.

This news release may include statements that constitute forward-looking statements, usually containing the words "believe," "estimate," "project," "expects" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this news release.


'/>"/>
SOURCE Global Med Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NanoPass Makes its MicronJet Technology Available to Increase Global Supply of Pandemic Influenza Vaccines
2. APHL Chosen by PEPFAR to Develop Global Health Laboratory Systems
3. Lumension Expands Global Footprint and Strengthens Capabilities with the Opening of a New Development Office in Ireland
4. HeartWare to Present at Canaccord Adams 29th Annual Global Growth Conference
5. NBTY to Web Cast Presentation at Canaccord Adams Global Growth Conference; Announces Preliminary Unaudited Net Sales Results for July 2009
6. WebMD to Present at the Canaccord Adams 29th Annual Global Growth Conference
7. Transition Therapeutics to Present at Canaccord Adams 29th Annual Global Growth Conference
8. Inverness Medical Innovations to Present at the Canaccord Adams Global Growth Conference on August 11, 2009
9. Osteotech to Present at the Canaccord Adams 29th Annual Global Growth Conference
10. Cyberonics to Present at Canaccord Adams 29th Annual Global Growth Conference
11. Global Health Trax, Inc. Announces New Marketing Campaign for Oxygen Elements Max Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is ... a fitness app. The fitness app plans to fix the two major problems leading the ... one size fits all type program , They don’t eliminate all the reasons ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 ... brings up a new, often overlooked aspect of head lice: the parasite’s ability to live ... not a common occurrence, but a necessary one in the event that lice have simply ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... addition of the "Structural Electronics 2015-2025: Applications, ... In-Mold Electronics, Smart ... Integrated Photovoltaics Structural electronics involves ... as load-bearing, protective structures, replacing dumb structures such ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, 2016 ... mobile pulmonary function testing company, is now able to perform sophisticated ... by ndd Medical Technologies , Inc. Patients ... hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients ... get any needed testing done in the comfort of her own ...
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
Breaking Medicine Technology: